AG
FLXN

Advisor Group’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Advisor Group’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$54K Sell
2,619
-3,820
-59% -$64.4K ﹤0.01% 3373
2019
Q3 		$88K Buy
6,439
+3,680
+133% +$43.7K ﹤0.01% 2986
2019
Q2 		$34K Sell
2,759
-4,448
-62% -$51.3K ﹤0.01% 3637
2019
Q1 		$90K Sell
7,207
-1,401
-16% -$18.7K ﹤0.01% 2954
2018
Q4 		$97K Buy
8,608
+3,490
+68% +$54.7K ﹤0.01% 2678
2018
Q3 		$95K Buy
5,118
+3,168
+162% +$72.8K ﹤0.01% 2796
2018
Q2 		$50K Sell
1,950
-7,600
-80% -$197K ﹤0.01% 3116
2018
Q1 		$214K Buy
9,550
+950
+11% +$23.2K ﹤0.01% 1928
2017
Q4 		$215K Buy
8,600
+1,300
+18% +$31.8K ﹤0.01% 1946
2017
Q3 		$177K Buy
7,300
+2,100
+40% +$49.4K ﹤0.01% 1945
2017
Q2 		$105K Buy
5,200
+3,500
+206% +$72.9K ﹤0.01% 2271
2017
Q1 		$46K Hold
1,700
– – ﹤0.01% 2789
2016
Q4 		$32K Hold
1,700
– – ﹤0.01% 2929
2016
Q3 		$33K Buy
+1,700
New +$28.8K ﹤0.01% 2837

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Advisor Group's FLXN Position: Q4 2019 in Review

Advisor Group reduced its Flexion Therapeutics, Inc. (FLXN) stake by 59% in Q4 2019, selling an estimated $64.4K and leaving 2,619 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.

Advisor Group first reported a position in FLXN in Q3 2016 and has held it in 14 quarters since. The position peaked at $215K in Q4 2017. 133 funds tracked by Wall St. Rank hold FLXN as of Q4 2019.

  • Advisor Group held 2,619 shares of Flexion Therapeutics, Inc. worth $54K as of Q4 2019.
  • Advisor Group sold 3,820 Flexion Therapeutics, Inc. shares in Q4 2019, an estimated $64.4K.
  • Flexion Therapeutics, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3373 holding.
  • Advisor Group first reported a position in Flexion Therapeutics, Inc. in Q3 2016 and has held it in 14 quarters since.
  • Advisor Group's Flexion Therapeutics, Inc. position peaked at $215K in Q4 2017.
  • 133 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.